Stockreport

Highest risk CLL patients may benefit from CAR T with BTK inhibitor [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Johnson & Johnson's (J&J's) Imbruvica (ibrutinib) for relapsed/refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) were presented at the A [Read more]